<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It is generally believed that shutting down the kinase activity of BCR-ABL by <z:chebi fb="0" ids="45783">imatinib</z:chebi> will completely inhibit its functions, leading to inactivation of its downstream signaling pathways and cure of the disease </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="45783">Imatinib</z:chebi> is highly effective at treating human <z:e sem="disease" ids="C0856536" disease_type="Neoplastic Process" abbrv="">Philadelphia chromosome-positive</z:e> (Ph(+)) <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase but not Ph(+) B cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) and <z:mp ids='MP_0005481'>CML</z:mp> <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We find that SRC kinases activated by BCR-ABL remain fully active in <z:chebi fb="0" ids="45783">imatinib</z:chebi>-treated mouse leukemic cells, suggesting that <z:chebi fb="0" ids="45783">imatinib</z:chebi> does not inactivate <z:hpo ids='HP_0000001'>all</z:hpo> BCR-ABL-activated signaling pathways </plain></SENT>
<SENT sid="3" pm="."><plain>This SRC pathway is essential for leukemic cells to survive <z:chebi fb="0" ids="45783">imatinib</z:chebi> treatment and for <z:mp ids='MP_0005481'>CML</z:mp> transition to lymphoid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Inhibition of both SRC and BCR-ABL kinase activities by <z:chebi fb="0" ids="49375">dasatinib</z:chebi> affords complete <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> remission </plain></SENT>
<SENT sid="5" pm="."><plain>However, curing <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> and <z:mp ids='MP_0005481'>CML</z:mp> mice requires killing leukemic stem cells insensitive to both <z:chebi fb="0" ids="45783">imatinib</z:chebi> and <z:chebi fb="0" ids="49375">dasatinib</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Besides BCR-ABL and SRC kinases, stem cell pathways must be targeted for curative therapy of Ph(+) <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>